MA27167A1 - ACIDES 3-(IMIDAZOLYL)-2-ALKOXYPROPANOiQUES SERVANT D'INHIBITEURS DE TAFIa. - Google Patents
ACIDES 3-(IMIDAZOLYL)-2-ALKOXYPROPANOiQUES SERVANT D'INHIBITEURS DE TAFIa.Info
- Publication number
- MA27167A1 MA27167A1 MA27786A MA27786A MA27167A1 MA 27167 A1 MA27167 A1 MA 27167A1 MA 27786 A MA27786 A MA 27786A MA 27786 A MA27786 A MA 27786A MA 27167 A1 MA27167 A1 MA 27167A1
- Authority
- MA
- Morocco
- Prior art keywords
- imidazolyl
- january
- optionally substituted
- hydrogen atom
- alkoxypropanoic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
DEPOSANT Société dite: PFIZER INC. REVENDICATION DE PRIORITES GB 22 Janvier 2002 0201389.4 GB 22 Janvier 2002 0202027.9 Voir en annexe le titre de l'invention et le texte de l'abrégé Acides 3-(imidazolyl)-2-alkoxypropanoïques servant d'inhibiteurs de TAFIa Les composés répondant à la formule (I) dans laquelle n a une valeur de 0 à 3, R1 représente un groupe, facultativement substitué, alkyle en C1 à C6, alcényle en C2 à C6 ou alcynyle en C2 à C6, un hétérocycle, un hétérocycle aromatique, un groupe aryle ou un atome d'hydrogène et R2, R3, R4, R5, R6, R7, R8 et R9 sont choisis chacun indépendamment entre un atome d'hydrogène et un groupe alkyle en C1 à C6 facultativement substitué, ou bien R5 et R8 représentent une chaîne alkylène, sont nouveaux. Ils sont utiles dans le traitement de troubles thrombotiques et d'autres pathologies associées au dépôt de fibrine.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0201389A GB0201389D0 (en) | 2002-01-22 | 2002-01-22 | 3-(imidazolyl)-2-alkoxypropanoic acids |
| GB0202027A GB0202027D0 (en) | 2002-01-29 | 2002-01-29 | 3-(imidazolyl)-2-alkoxypropanoic acids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA27167A1 true MA27167A1 (fr) | 2005-01-03 |
Family
ID=27614792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA27786A MA27167A1 (fr) | 2002-01-22 | 2004-07-15 | ACIDES 3-(IMIDAZOLYL)-2-ALKOXYPROPANOiQUES SERVANT D'INHIBITEURS DE TAFIa. |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP1467731A1 (fr) |
| JP (1) | JP2005520811A (fr) |
| KR (1) | KR20040077775A (fr) |
| CN (1) | CN1620291A (fr) |
| AP (1) | AP2004003084A0 (fr) |
| AR (1) | AR038197A1 (fr) |
| BR (1) | BR0307016A (fr) |
| CA (1) | CA2472238A1 (fr) |
| EA (1) | EA200400716A1 (fr) |
| EC (1) | ECSP045200A (fr) |
| HR (1) | HRP20040659A2 (fr) |
| IL (1) | IL162677A0 (fr) |
| IS (1) | IS7310A (fr) |
| MA (1) | MA27167A1 (fr) |
| MX (1) | MXPA04006573A (fr) |
| NO (1) | NO20043457L (fr) |
| OA (1) | OA12756A (fr) |
| PA (1) | PA8563501A1 (fr) |
| PE (1) | PE20030929A1 (fr) |
| PL (1) | PL371487A1 (fr) |
| TN (1) | TNSN04121A1 (fr) |
| TW (1) | TW200302094A (fr) |
| UY (1) | UY27615A1 (fr) |
| WO (1) | WO2003061652A1 (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005051384A1 (fr) * | 2003-11-25 | 2005-06-09 | Pfizer Limited | Compositions pharmaceutiques stabilisees |
| JP2008536923A (ja) * | 2005-04-18 | 2008-09-11 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | 心筋の再灌流の増強およびｐｃｉの容易化のためのｔａｆｉ阻害剤の使用 |
| WO2010050525A1 (fr) | 2008-10-29 | 2010-05-06 | 大正製薬株式会社 | Composé ayant une activité inhibitrice des tafia |
| AU2009322342A1 (en) * | 2008-12-05 | 2011-06-30 | Merck Sharp & Dohme Corp. | Morpholinone compounds as factor IXa inhibitors |
| US8987242B2 (en) | 2008-12-05 | 2015-03-24 | Merck Sharp & Dohme Corp. | Morpholinone compounds as factor IXA inhibitors |
| RS56445B1 (sr) * | 2010-03-18 | 2018-01-31 | Daiichi Sankyo Co Ltd | Cikloalkil-supstituisani imidazolni derivat |
| KR20130006620A (ko) | 2010-03-18 | 2013-01-17 | 다이이찌 산쿄 가부시키가이샤 | 시클로프로판카르복실산 유도체 |
| AU2014280329A1 (en) | 2013-06-10 | 2016-01-07 | Sanofi | Macrocyclic urea derivatives as inhibitors of TAFIa, their preparation and their use as pharmaceuticals |
| EP3437641A4 (fr) | 2016-03-29 | 2019-11-20 | Daiichi Sankyo Company, Limited | Agent thérapeutique contre les maladies inflammatoires de l'intestin |
| US11512067B2 (en) | 2017-09-14 | 2022-11-29 | Daiichi Sankyo Company, Limited | Compound having cyclic structure |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9901572D0 (sv) * | 1999-05-03 | 1999-05-03 | Astra Ab | New compounds |
| OA12362A (en) * | 2000-08-17 | 2004-04-07 | Pfizer | Substituted imidazoles as tafia inhibitors. |
-
2003
- 2003-01-10 PL PL03371487A patent/PL371487A1/xx unknown
- 2003-01-10 JP JP2003561596A patent/JP2005520811A/ja active Pending
- 2003-01-10 CN CNA03802599XA patent/CN1620291A/zh active Pending
- 2003-01-10 CA CA002472238A patent/CA2472238A1/fr not_active Abandoned
- 2003-01-10 AP APAP/P/2004/003084A patent/AP2004003084A0/en unknown
- 2003-01-10 KR KR10-2004-7011370A patent/KR20040077775A/ko not_active Application Discontinuation
- 2003-01-10 EP EP03700059A patent/EP1467731A1/fr not_active Withdrawn
- 2003-01-10 OA OA1200400190A patent/OA12756A/en unknown
- 2003-01-10 MX MXPA04006573A patent/MXPA04006573A/es unknown
- 2003-01-10 BR BR0307016-6A patent/BR0307016A/pt not_active IP Right Cessation
- 2003-01-10 EA EA200400716A patent/EA200400716A1/ru unknown
- 2003-01-10 WO PCT/IB2003/000060 patent/WO2003061652A1/fr not_active Application Discontinuation
- 2003-01-10 IL IL16267703A patent/IL162677A0/xx unknown
- 2003-01-16 TW TW092100889A patent/TW200302094A/zh unknown
- 2003-01-17 PE PE2003000058A patent/PE20030929A1/es not_active Application Discontinuation
- 2003-01-20 UY UY27615A patent/UY27615A1/es not_active Application Discontinuation
- 2003-01-21 AR ARP030100165A patent/AR038197A1/es unknown
- 2003-01-22 PA PA20038563501A patent/PA8563501A1/es unknown
-
2004
- 2004-06-14 IS IS7310A patent/IS7310A/is unknown
- 2004-06-30 TN TNP2004000121A patent/TNSN04121A1/en unknown
- 2004-07-15 MA MA27786A patent/MA27167A1/fr unknown
- 2004-07-19 HR HR20040659A patent/HRP20040659A2/hr not_active Application Discontinuation
- 2004-07-22 EC EC2004005200A patent/ECSP045200A/es unknown
- 2004-08-19 NO NO20043457A patent/NO20043457L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2472238A1 (fr) | 2003-07-31 |
| BR0307016A (pt) | 2004-11-03 |
| IL162677A0 (en) | 2005-11-20 |
| TNSN04121A1 (en) | 2006-06-01 |
| CN1620291A (zh) | 2005-05-25 |
| ECSP045200A (es) | 2004-08-27 |
| UY27615A1 (es) | 2003-08-29 |
| AP2004003084A0 (en) | 2004-09-30 |
| WO2003061652A1 (fr) | 2003-07-31 |
| WO2003061652A8 (fr) | 2004-09-10 |
| MXPA04006573A (es) | 2004-10-04 |
| EP1467731A1 (fr) | 2004-10-20 |
| PE20030929A1 (es) | 2003-11-05 |
| TW200302094A (en) | 2003-08-01 |
| PL371487A1 (en) | 2005-06-13 |
| HRP20040659A2 (en) | 2004-10-31 |
| EA200400716A1 (ru) | 2004-12-30 |
| JP2005520811A (ja) | 2005-07-14 |
| IS7310A (is) | 2004-06-14 |
| OA12756A (en) | 2006-07-03 |
| AR038197A1 (es) | 2005-01-05 |
| KR20040077775A (ko) | 2004-09-06 |
| PA8563501A1 (es) | 2004-08-31 |
| NO20043457L (no) | 2004-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA28020A1 (fr) | Phényl-ou pyridylamides servant d'antagonistes de la prostaglandine E2 | |
| MA27180A1 (fr) | N-aryl-2-oxazolidinone-5-carboxamides et leurs derives, et leur utilisation comme agents antibacteriens | |
| MA28271A1 (fr) | Dérivés de benzènesulfonylamino-pyridine -2-yle et composés apparentés servant d'inhibiteurs de la 11-bêta- hydroxystéroïde-déshydrogénase de type 1(11-bêta-HSD-1)pour le traitement du diabète et de l'obésité | |
| MA26875A1 (fr) | Composes azapolycycliques a noyau aryle condensé | |
| MA27448A1 (fr) | Derives de pyridine modulateurs du recepteur cb2 | |
| MA27452A1 (fr) | Derives d'indole servant d'agonistes beta-2 | |
| MA27167A1 (fr) | ACIDES 3-(IMIDAZOLYL)-2-ALKOXYPROPANOiQUES SERVANT D'INHIBITEURS DE TAFIa. | |
| MA27726A1 (fr) | Derives de 4-(4-(heterocyclylalkoxy)phenyl-1-(heterocyclyl-carbonyl) piperidine et composes associes servant d'antagonistes d'histamine h3 destines au traitement de troubles neurologiques | |
| BE903103A (fr) | Derives heterocycliques | |
| MA26989A1 (fr) | Derives de pyridine inhibiteurs de metalloproteinases de matrice | |
| DE60119894D1 (de) | Piperidinverbindungen und diese enthaltenden medikamente | |
| TNSN05104A1 (fr) | Derives de thiazole pour le traitement de troubles neurodegeneratifs | |
| MA30428B1 (fr) | Derives de dihydropyrazolopyrimidinones | |
| MA27573A1 (fr) | Sinomenine et derives de sinomenine, synthese et utilisation. | |
| TN2009000204A1 (fr) | Spirocetones servant d'inhibiteurs d'acetyl-coa-carboxylase | |
| TNSN07021A1 (fr) | Derives de quinazoline -4-yl-piperidine et cinnoline -4-yl-piperidine servant d'inhibiteurs de pde10 pour le traitement de troubles du snc | |
| MA26985A1 (fr) | Derives d'amides de thiazolyl-,oxazolyl-pyrrolyl-et imidazolyl-acides utiles comme inhibiteurs d'isozymes pde4 | |
| TNSN07178A1 (fr) | N-sulfonylaminobenzyl-2-phenoxy-acetamides substitues | |
| MA27439A1 (fr) | Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase | |
| TNSN06386A1 (fr) | Derives de tetraazabenzo [e] azulene et leurs analogues | |
| MA27144A1 (fr) | Benzamide et heteroarylamide servant d'antagonistes du recepteur p2x7 | |
| MA33832B1 (fr) | Isoquinolinones et quinazolinones substituées | |
| MA26996A1 (fr) | Derives de glutaramide a substituant n-phenpropylcyclopentyle, servant d'inhibiteurs de nep pour un trouble d'eveil sexuel feminin | |
| TNSN07366A1 (fr) | Tetrahydro-pyridoazepine -8- ones et composes apparentes, pour le traitement de la schizophrenie | |
| NO20064238L (no) | Imidazolinderivater med CB1 agonistlsk aktivitet |